Thank you for your constructive review! We uploaded the revised version of the manuscript with the revisions being highlighted. We made a reference to the most important biomarkers for the utilization of immune checkpoint inhibitors, explaining their significance for the prediction of the outcomes. We also made a reference to the types of tumor vaccines.

According to the clinical toxicity status of immunosuppressants, we do not elaborate in the issue of immunosuppression, but we mention that 4th generation CAR-T cell therapy avoids immunosuppression. Thank you once again for your comments!

Reviewer 1:

Thank you for your constructive review! We uploaded the revised version of the manuscript with the revisions being highlighted.

- According to the clinical toxicity status of immunosuppressants, we do not elaborate in the issue of immunosuppression, but we mention that 4th generation CAR-T cell therapy avoids immunosuppression.
- We made a reference to the most important biomarkers for the utilization of immune checkpoint inhibitors, explaining their significance for the prediction of the outcomes. Thank you once again for your comments!

Reviewer 2:

Thank you for your constructive review! We uploaded the revised version of the manuscript with the revisions being highlighted .

- We made a reference to the types of tumor vaccines.
- We made a reference to the most important biomarkers for the utilization of immune checkpoint inhibitors, explaining their significance for the prediction of the outcomes. Thank you once again for your comments!